PD-L1 and the risk of bacterial infection in patients with chronic liver diseases: An international multicohort study
| dc.coverage | DOI: 10.1016/j.jhepr.2025.101597 | |
| dc.creator | Juanola, Adrià | |
| dc.creator | Mezzano, Gabriel | |
| dc.creator | Pose, Elisa | |
| dc.creator | Moreta, Maria J. | |
| dc.creator | Incicco, Simone | |
| dc.creator | Gagliardi, Roberta | |
| dc.creator | Johansen, Stine | |
| dc.creator | Torp, Nikolaj | |
| dc.creator | Israelsen, Mads | |
| dc.creator | Jiménez-Esquivel, Natalia | |
| dc.creator | Castillo-Iturra, Joaquin | |
| dc.creator | Ribera, Jordi | |
| dc.creator | Gratacós-Ginès, Jordi | |
| dc.creator | Soria, Anna | |
| dc.creator | Cárdenas, Andrés | |
| dc.creator | Pérez-Guasch, Martina | |
| dc.creator | Cervera, Marta | |
| dc.creator | Nadal, Ruth | |
| dc.creator | Herms, Queralt | |
| dc.creator | Tonon, Marta | |
| dc.creator | Hansen, Torben | |
| dc.creator | Stankevic, Evelina | |
| dc.creator | Huang, Yun | |
| dc.creator | Vargas, Victor | |
| dc.creator | Zaccherini, Giacomo | |
| dc.creator | Alessandria, Carlo | |
| dc.creator | Uschner, Frank E. | |
| dc.creator | Beuers, Ulrich | |
| dc.creator | Francoz, Claire | |
| dc.creator | Mookerjee, Rajeshwar P. | |
| dc.creator | Laleman, Wim | |
| dc.creator | Solé, Cristina | |
| dc.creator | Bañares, Rafael | |
| dc.creator | Cuyàs, Berta | |
| dc.creator | Ariza, Xavi | |
| dc.creator | Coll, Mar | |
| dc.creator | Graupera, Isabel | |
| dc.creator | Fabrellas, Núria | |
| dc.creator | Morales-Ruiz, Manuel | |
| dc.creator | Thiele, Maja | |
| dc.creator | Krag, Aleksander | |
| dc.creator | Angeli, Paolo | |
| dc.creator | Piano, Salvatore | |
| dc.creator | Solà, Elsa | |
| dc.creator | Ginès, Pere | |
| dc.date | 2025 | |
| dc.date.accessioned | 2026-01-05T21:10:17Z | |
| dc.date.available | 2026-01-05T21:10:17Z | |
| dc.description | <p>Background & Aims: Impaired phagocytic capacity due to activation of the PD-1/PD-L1 pathway has been implicated in the development of bacterial infections in patients with cirrhosis. Soluble PD-L1 (sPD-L1) is easily measurable in plasma and has been proposed as a biomarker of sepsis. In the current study, we aim to evaluate the role of sPD-L1 as a biomarker of bacterial infection development in patients with cirrhosis. Methods: Plasma samples from 995 patients with chronic liver disease grouped in three cohorts were analyzed: an initial cohort of 268 hospitalized patients with acute decompensated cirrhosis, 327 out-patients with non-acute decompensated cirrhosis and finally 400 patients with high-risk alcohol consumption, including all stages of liver fibrosis, from mild/no fibrosis to cirrhosis (F0–F4). The main outcomes of the study were development of bacterial infection and mortality. Results: Patients who developed bacterial infections had higher median levels of sPD-L1 than those who did not (160 [IQR 116-221] vs. 136 [IQR 97-193] pg/ml, respectively, p value <0.001; hazard ratio 1.034, 95% CI 1.014-1.055). Levels of sPD-L1 were associated with bacterial infection development after adjustment for confounding factors. During follow-up, patients who died had higher median sPD-L1 levels than survivors, after adjustment for MELD Na (180 [IQR 143-267] vs. 134 [IQR 97-187] pg/ml, respectively; p value <0.001; HR 1.066, 95% CI 1.043-1.089). These findings were observed in all cohorts. Conclusions: Plasma levels of sPD-L1 are associated with the risk of bacterial infection development irrespective of the stage of chronic liver disease. Furthermore, higher sPD-L1 levels are linked to increased mortality. Measurement of sPD-L1 levels may help identify patients at high risk of developing bacterial infections and guide the implementation of new preventive strategies. Impact and implications: This study explores the role of soluble PD-L1 as a biomarker of immune dysfunction and its association with clinical outcomes in patients with chronic liver disease. Our findings demonstrate that soluble PD-L1 levels increase with the progression of liver disease and they are independently associated with an increased risk of bacterial infection development and mortality. These results could help physicians identify high-risk individuals earlier and implement preventive strategies.</p> | eng |
| dc.identifier | https://investigadores.uandes.cl/en/publications/ab15fd3e-bff7-4730-9a4f-4d765f8ec3b2 | |
| dc.identifier.uri | https://repositorio.uandes.cl/handle/uandes/64274 | |
| dc.language | eng | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.source | vol.7 (2025) nr.12 | |
| dc.subject | Bacterial infection | |
| dc.subject | Biomarkers | |
| dc.subject | Decompensated cirrhosis | |
| dc.subject | Liver cirrhosis | |
| dc.subject | Mortality | |
| dc.subject | PD-L1 | |
| dc.title | PD-L1 and the risk of bacterial infection in patients with chronic liver diseases: An international multicohort study | eng |
| dc.type | Article | eng |
| dc.type | Artículo | spa |